Trials Sponsors Conditions Drugs Pricing

Conditions

Lymphoma Lymphoproliferative Syndrome, Autoimmune

Outcome Measures

Primary Outcomes (1)

Incidence and prevalence of lymphomas/lymphoproliferative syndromes referred to the Centre between January 1980 and September 2021
Incidence and prevalence
through study completion, an average of 6 years

Secondary Outcomes (12)

Overall Survival (OS)
through study completion, an average of 6 years
event free survival (EFS)
through study completion, an average of 6 years
Lymphoma specific survival (LSS)
through study completion, an average of 6 years
Progression Free Survival (PFS)
through study completion, an average of 6 years
Net survival (5 years)
through study completion, an average of 6 years
+7 more secondary outcomes

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021

You may qualify if:

Age greater than or equal to 18 years of enrollment

Sponsors & Collaborators

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Otherlead

Study Sites (1)

IRCCS Azienda Ospedaliero - Universitaria di Bologna

Bologna, Bologna, 40138, Italy

RECRUITING

Pier Luigi Zinzani, MDCONTACT+390512143680 pierluigi.zinzani@unibo.it

Alessandro Broccoli, MDCONTACT+390512143680 Alessandro.broccoli@studio.unibo.it

Pier Luigi Zinzani, MDCONTACT

MeSH Terms

Conditions

Autoimmune Lymphoproliferative SyndromeLymphoma

Condition Hierarchy (Ancestors)

Lymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesAutoimmune DiseasesImmune System DiseasesImmunoproliferative DisordersNeoplasms by Histologic TypeNeoplasms

Study Officials

Pier Luigi Zinzani, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
PRINCIPAL INVESTIGATOR

Central Study Contacts

Pier Luigi Zinzani, MD

CONTACT

+390512143680 pierluigi.zinzani@unibo.it

Alessandro Broccoli, MD

CONTACT

+390512143680

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 3, 2024

First Posted

January 17, 2025

Study Start

February 1, 2022

Actual (reported)

Primary Completion

December 31, 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Retrospective Observational Study of Italian Cohort of Lymphoma Patients (RETRO-LYMPH)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (12)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (12)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations